AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GKOS

Glaukos Q3 Earnings Call Highlights

Glaukos (GKOS) reported Q3 revenue of $118.6M, up 47% YoY, with iDose TR generating $76M. The company expects full-year 2026 iDose revenue to reach low-$280M. Glaukos also announced disease-awareness campaigns and pipeline updates, including FDA approval targets for iDose TRIO by late 2027.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

Strong earnings and guidance may trigger short‑covering and buying interest.

02

Market read

Earnings beat and raised guidance provide fresh catalyst for GKOS, with potential sector spillover.

03

What to watch

Potential LCD restrictions could cap revenue upside despite current guidance.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Glaukos (NYSE:GKOS) reported Q3 results, new product sales, and upcoming trial readouts.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Q3 earnings call disclosed $118.6M revenue, $76M iDose TR sales, raised full-year iDose revenue guidance to $280M, and positive Phase IV trial results.

Expected impact

likely upward pressure as market prices in higher revenue outlook and clinical success

Evidence & confidence

Revenue beat, higher guidance, and positive trial data are fresh material that can lift the stock.

Market effects

Sector

May boost sentiment for the ophthalmic device and broader eye‑care sector.

Regional

Positive for U.S. healthcare equities, especially med‑tech.

Global

Limited to eye‑care niche; no broad macro effect.

Counterpoint

What could challenge this read

If reimbursement challenges materialize, guidance could be revised down.

Key entities

  • company
    Glaukos Corporation

    Ophthalmic medical‑technology firm.

  • person
    Stephen Curry

    NBA champion featured in disease‑awareness campaign.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com